Indications - Jakavi
Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera...
- Twitter Linkedin Facebook Pinterest Google plus
Efficacy
Indication
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (APPLY-PNH)...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1 .Twitter Linkedin Facebook Pinterest Google plusReimbursement
Mechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plusDosing
Dosing¹
Posology & Method of AdministrationThe recommended dose is 200 mg taken orally twice daily.
Healthcare professionals should advise patients with PNH about the...
Twitter Linkedin Facebook Pinterest Google plusUnmet Need
Controlled Access